Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Experimental scrutiny and project timelines : an example

Dooley, N. and Ford, S. J. and Prasad, Elke and Elliott, M. and Halbert, Gavin (2010) Experimental scrutiny and project timelines : an example. Journal of Pharmacy and Pharmacology, 62 (10). pp. 1208-1209. ISSN 0022-3573

[img]
Preview
PDF
Download (542Kb) | Preview

    Abstract

    AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.

    Item type: Article
    ID code: 37133
    Notes: ABSTRACTS FROM THE UK-PHARMSCI CONFERENCE, 1–3 SEPTEMBER 2010
    Keywords: tyrosine kinases , cancer research, experimental analysis, Therapeutics. Pharmacology, Pharmaceutical Science, Pharmacology
    Subjects: Medicine > Therapeutics. Pharmacology
    Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
    Related URLs:
      Depositing user: Pure Administrator
      Date Deposited: 26 Jan 2012 16:09
      Last modified: 06 Sep 2014 00:23
      URI: http://strathprints.strath.ac.uk/id/eprint/37133

      Actions (login required)

      View Item

      Fulltext Downloads: